Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Goss C, Avecilla ST, Garbaini J, Degtyaryova D, Lo D, Chang DY, et al. Can the interval between antibody identifications be increased for alloimmunized patients? Transfusion. 2016;56(2):334-8.

Magro CM, Momtahen S, Verma S, Abraham RM, Friedman C, Nuovo GJ, et al. Cutaneous myeloid dendritic cell dyscrasia: A cutaneous clonal monocytosis associated with chronic myeloproliferative disorders and peripheral blood monocytosis. Ann Diagn Pathol. 2016;25:85-91.

Kumar B, Khaleghzadegan S, Mears B, Hatano K, Kudrolli TA, Chowdhury WH, et al. Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening. Oncotarget. 2016;7(45):72593-72607.

Liang L, Olar A, Niu N, Jiang Y, Cheng W, Bian X-, et al. Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases. Am J Surg Pathol. 2016;40(6):847-56.

Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J, et al. NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria. Cell. 2016;164(5):896-910.

Marin EP, József L, Di Lorenzo A, Held KF, Luciano AK, Melendez J, et al. The Protein Acyl Transferase ZDHHC21 Modulates α1 Adrenergic Receptor Function and Regulates Hemodynamics. Arterioscler Thromb Vasc Biol. 2016;36(2):370-9.

Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298-305.

Saab J, Qin L, Jessurun J. Granulomatous Insulitis as a Cause of Acute-Onset Insulin-Dependent Diabetes Mellitus in a Patient With a Pancreatic Endocrine Carcinoma. Int J Surg Pathol. 2016;24(7):648-52.

Wike CL, Graves HK, Hawkins R, Gibson MD, Ferdinand MB, Zhang T, et al. Aurora-A mediated histone H3 phosphorylation of threonine 118 controls condensin I and cohesin occupancy in mitosis. Elife. 2016;5:e11402.

Rudman SM, Gray KP, Batista JL, Pitt MJ, Giovannucci EL, Harper PG, et al. Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU Int. 2016;118(6):919-926.